Compare Innodata Inc (INOD) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Tempus AI — how do they compare? Innodata Inc trades at $61.78 (market cap $2.18B), while Tempus AI trades at $69.95 (market cap $12.77B). The key difference: Tempus AI is far larger — about 5.9× Innodata Inc's market cap, and Tempus AI is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 19 Days and Tempus AI for 22 Days on average.
| INOD | TEM | |
|---|---|---|
Market Cap | $2.18B | $12.77B |
Volume | 1,415,262 | 8,980,490 |
Sector | Technology | Broad Market / Factor |
52-Week High | $121.50 | $99.28 |
52-Week Low | $34.45 | $41.55 |
Typical Hold Time | 19 Days | 22 Days |
Enterprise Value | $1.93B | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD trades at $63.42, down 4.26% today, but maintains strong technical support near $63. The company demonstrates robust fundamentals with revenue growing from $252M in 2025 to $317M in 2026 and net income expanding from $32M to $46M. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $0.42 surpassing the $0.13 estimate. Analyst sentiment remains positive with a 66.7% buy rating consensus.
INOD presents growth potential through its AI data engineering services and new motion-capture lab expansion, though premium valuation metrics (P/E 49.12, P/S 6.91) and customer concentration risks warrant caution. The stock's technical positioning near key support levels combined with strong earnings momentum supports a constructive outlook for investors seeking AI infrastructure exposure.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
